Moleculin Biotech enters $6.5M ATM equity offering with Roth Capital

Moleculin Biotech, Inc.

Enters ATM agreement to sell up to $6.5M of common stock via Roth Capital as agent.
Placement fee of 3.0% of gross proceeds; Roth Capital reimbursed up to $50k legal fees.
Proceeds to be used for working capital and general corporate purposes.
Sales will be made under existing effective shelf registration statement (File No. 333-280064).
Offering may be suspended by either party; no obligation to sell any shares.

item 1.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.